Latest Quarterly Report
Filed: 2026-05-12
Key Insights
- Coya Therapeutics completed a January 2026 private placement offering, indicating ongoing capital raises to fund clinical development and operations, which is typical for pre-revenue or early-stage biotech companies.
- The company maintains multiple development agreements including DRL Development Agreement and Patent/Know-How License Agreements, suggesting active collaboration on drug candidate development across different therapeutic areas.
- The filing shows significant R&D and G&A expense tracking across Q1 2026, with detailed segmentation of internal R&D costs and stock-based compensation, reflecting the capital-intensive nature of clinical-stage biopharmaceutical development.
- Substantial warrant and convertible debt instruments are outstanding from multiple private placements and offerings, which could create significant dilution to existing shareholders upon conversion or exercise.